Living Cell Technologies (ASX:LCT) touted data today showing its NTCell cell therapy is safe 130 weeks after treatment in a Phase I/IIa Parkinson’s trial. The study’s primary endpoint was safety. The trial, which enrolled and treated 4 patients, involved implanting 40 NTCell capsules into 1 side of the brain. The company reported that treatment with […]
BioCorRx partners with virtual reality center for naltrexone implant study
BioCorRx (OTC:BICX) said today that it partnered with the Virtual Reality Medical Center to conduct a study on the company’s long-lasting naltrexone implant. BioCorRx’s recovery program consists of a long-lasting implant that delivers an opioid antagonist, naltrexone, which reduces physical cravings for alcohol and opioids. The recovery service also has a counseling program specifically designed […]
Intersect ENT updates on Sinuva steroid-releasing sinus implant
Intersect ENT (NSDQ:XENT) said today that the FDA is slated to make a decision on its new drug application for the Sinuva steroid-releasing sinus implant by January 7, 2018. The Sinuva implant, which was previously called the Resolve implant, is placed during an in-office doctors appointment and is designed to be a treatment option for […]
Infertility: There could be a 3D printing solution
New Northwestern University research offers a potential 3D printing solution for women’s infertility – providing hope for cancer survivors who want to start families. The Northwestern researchers successfully 3D printed a bioprosthetic mouse ovary that ovulated when implanted inside a live mouse. Mice with the bioprosthetic ovaries were able to give birth to live pups, […]
NanoMedical Systems raises $4.1m
NanoMedical Systems raised $4.1 million in a new round of financing, according to a regulatory filing. The Delaware-based company offered equity and warrants to the 46 investors that contributed to the round. The company did not disclose how it plans to use its newly-acquired funds. No money from the round is slated to compensate sales […]
Study: pSivida’s Durasert lessens recurrence of uveitis through 12 months
pSivida (NSDQ:PSDV) touted 1-year follow-up data yesterday for the company’s Durasert 3-year treatment of posterior segment uveitis. The data, which was presented at the Association for Research in Vision and Ophthalmology annual meeting, is from pSivida’s 1st phase III trial. The data showed that the 3-year uveitis implant significantly reduced the recurrence of posterior segment uveitis […]
Systemic therapy beats Bausch & Lomb implant in NIH uveitis study
Systemic therapy of corticosteroids and immunosuppressants better preserved vision in patients with uveitis compared to Bausch & Lomb‘s long-lasting corticosteroid intraocular implant in a clinical trial supported by the National Eye Institute, a branch of the National Institutes of Health. In 7 years, visual acuity remained stable in patients receiving systemic therapy and declined by […]
Glaukos shares tumble despite Q1 beat
Shares in Glaukos (NYSE:GKOS) fell -10% today after the ophthalmic medtech company beat expectations on Wall Street with its 1st quarter results. The San Clemente, Calif.-based company posted profits of $878,000, or 2¢ per share, on sales of $35.9 million for the 3 months ended March 31, for bottom-line loss of -2% on sales growth of […]
Intersect ENT beats Q1 earnings, rev forecast
Shares in Intersect ENT (NSDQ:XENT) fell slightly yesterday after the drug-device maker met expectations on Wall Street with its 1st quarter results. The Menlo Park, Calif.-based company posted a loss of -$6.8 million, or -23¢ per share, on sales of $20.5 million for the 3 months ended March 31, for bottom-line growth of 20% on sales growth of 22.8% […]
Braeburn’s risperidone implant meets primary endpoint in schizophrenia trial
Braeburn Pharmaceuticals said yesterday that a 6-month study of its risperidone implant in patients with schizophrenia or schizoaffective disorder met its primary endpoint. Risperidone, the most commonly-prescribed therapy for schizophrenia, depends on consistent administration, but patients with schizophrenia sometimes stop taking their medication when their symptoms improve. Long-acting, injectable formulations of risperidone are on the market, […]
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- Next Page »
